Skip to main content
EyePoint Pharmaceuticals, Inc. logo

EyePoint Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · EYPT ISIN · US74440J1016 LEI · 549300QE1RU34T50MR69 US Manufacturing
Open in API
Filings indexed 1,019 across all filing types
Latest filing 2012-05-09 Regulatory Filings
Country US United States of America
Listing US EYPT

About EyePoint Pharmaceuticals, Inc.

https://eyepointpharma.com/

EyePoint Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for serious retinal diseases. The company leverages its proprietary Durasert E™ technology, a bio-erodible platform for sustained intraocular drug delivery, to create durable therapies. Its lead investigational product, DURAVYU™ (EYP-1901), combines the tyrosine kinase inhibitor vorolanib with the Durasert E™ system for the potential treatment of VEGF-mediated retinal diseases. The company's goal is to improve patient outcomes and reduce treatment burden by providing long-lasting treatments for chronic eye conditions.

Recent filings

Filing Released Lang Actions
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text specifically mentions that the company issued a press release announcing its third quarter fiscal year 2012 results. The document includes a press release as an exhibit but does not contain detailed financial statements or substantive financial data itself. The length is only 2654 characters, which is quite short and consistent with an announcement rather than a full report. According to the rules, a short document announcing or furnishing a press release of financial results should be classified as a Regulatory Filing (RNS) rather than an Interim/Quarterly Report (IR) or Earnings Release (ER), since it is a Form 8-K filing and not the actual earnings release document itself. Therefore, the best classification is Regulatory Filings (RNS).
2012-05-09 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce unscheduled material events or corporate changes. The content discusses regulatory delays related to marketing authorizations for a product (ILUVIEN) in Europe, referencing another company's (Alimera Sciences) filing. It includes forward-looking statements and risk factors typical of such filings. There are no financial statements or detailed financial data present, nor is this an annual or quarterly report. The document is not a certification or a proxy statement, nor does it announce voting results or capital changes. It is an announcement of a material event, fitting the category of Regulatory Filings (RNS), which is the fallback for miscellaneous SEC filings like Form 8-K that do not fit other categories. The document length (5641 characters) and content confirm it is the filing itself, not just a report publication announcement.
2012-03-27 English
FORM 3
Director's Dealing
2012-03-13 English
FORM 8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The key content is the election of a new director to the board and related compensatory arrangements. This matches the description of Board/Management Information filings, which announce changes in the company's board of directors or senior management. The document is short (2702 characters) and focuses solely on management changes, not on financial results or other report types. Therefore, the appropriate classification is MANG (Board/Management Information).
2012-03-06 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K, which is a current report filed with the SEC to announce major events that shareholders should know about. The content includes an announcement about a regulatory approval event related to a product (ILUVIEN) and references a press release as an exhibit. The document is short (2371 characters) and primarily serves as a notification of an event rather than a detailed financial report or other specific filing type. It does not contain financial statements, management changes, earnings data, or other detailed report content. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2012-02-28 English
ORBIS INVESTMENT MANAGEMENT LIMITED
Major Shareholding Notification
2012-02-14 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.